Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
ad [2018/11/18 10:50]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
ad [2019/07/21 11:46] (current)
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
Line 4: Line 4:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^
-MCI and Mild AD | Intravenous anti-tau antibody ​ ​|  ​III  ​| ​ Yes  |  33%  |  ​18 months ​ |  ​5 years  | +| Mild to Moderate ​AD |  ​Antibiotic vs. P. gingivalis ​ ​|  ​II  ​| ​ Yes  |  33%  |  ​12 months ​ |  ​None  | 
-MCI and Mild AD | Oral BACE inhibitor ​|  ​III  ​| ​ Yes  |  ​50%  |  ​48 weeks  ​|  ​1+ years  |+| Mild to Moderate ​AD |  Oral neuroprotectant  ​|  ​II  ​| ​ Yes  |  ​33%  |  ​12 months ​|  ​none  |
 | MCI and Mild AD | Counterpulsation device |  III  |  Yes  |  50%  | 24 weeks  |  1 year  | | MCI and Mild AD | Counterpulsation device |  III  |  Yes  |  50%  | 24 weeks  |  1 year  |
-| Agitation in AD | Oral 5HT2A antagonist |  III  |  Yes  |  50%  |  8 weeks  |  None  | 
 | Agitation in AD | Oral combination of two approved drugs |  III  |  Yes  |  33%  |  5 weeks  |  None  |  | Agitation in AD | Oral combination of two approved drugs |  III  |  Yes  |  33%  |  5 weeks  |  None  | 
  
Print/export
QR Code
QR Code ad (generated for current page)